ImaginAb’s is developing Minibodies
that preserve their whole length while being inert in the body. Advancing the
pipeline of minibodies to target cancer, including CD8 ImmunoPET targeting CD8
T cells, the company believes its products can add quality to the lives of cancer
patients.
The company is already working with major pharma players such as Merck & Co., Boehringer Ingelheim, Nektar and Roche, some of the major players in cancer immunotherapy, backed by venture capital firms including The Parker Institute for Cancer Immunotherapy, Nextech Invest, Adage Capital, The Cycad Group, Merck (MSD) Pharma, Novartis Bioventures and Jim Pallotta of the Raptor Group.
Aytu BioScience enters into an
agreement with Cerecor to gain access to a portfolio of prescription products
for USD 17 Million.
The transaction will be done in two modes in cash worth USD 4.5 Million and USD 12.5 Million worth stocks. This agreement will add approximately USD 44 Million to the revenue of Aytu BioSciences. The revenue is also added by the previous acquisition of Innovus Pharmaceuticals.
The acquired assets consist of
six established primary pediatric care products including: AcipHex Sprinkle,
Cefaclor for Oral Suspension, Karbinal ER, Flexichamber, Poly-Vi-Flor and
Tri-Vi-Flor.
Aytu BioSciences is a company aiming to commercialize novel products to address patients’ needs, committed to treating problems like hypogonadism, severe cough and respiratory symptoms, insomnia, and male infertility.
Akorn, a leading
pharmaceutical firm, has recently received a new Abbreviated New Drug
Application (ANDA) approval the FDA for its betamethasone dipropionate lotion.
According to IQVIA, U.S. sales of
betamethasone dipropionate lotion (augmented), 0.05% were approximately $10
million for the twelve months ended August 2019.
Betamethasone dipropionate lotion, a strong corticosteroid, is used to treat several types of skin conditions like eczema, dermatitis, allergies, rash. Indicated to provide relief from inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older, it is manufactured at Akorn’s Amityville, New York manufacturing facility.
